238 related articles for article (PubMed ID: 11901097)
1. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.
Patrick JE; Kosoglou T; Stauber KL; Alton KB; Maxwell SE; Zhu Y; Statkevich P; Iannucci R; Chowdhury S; Affrime M; Cayen MN
Drug Metab Dispos; 2002 Apr; 30(4):430-7. PubMed ID: 11901097
[TBL] [Abstract][Full Text] [Related]
2. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia).
Ghosal A; Hapangama N; Yuan Y; Achanfuo-Yeboah J; Iannucci R; Chowdhury S; Alton K; Patrick JE; Zbaida S
Drug Metab Dispos; 2004 Mar; 32(3):314-20. PubMed ID: 14977865
[TBL] [Abstract][Full Text] [Related]
3. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe.
Ezzet F; Krishna G; Wexler DB; Statkevich P; Kosoglou T; Batra VK
Clin Ther; 2001 Jun; 23(6):871-85. PubMed ID: 11440287
[TBL] [Abstract][Full Text] [Related]
4. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins.
Oswald S; Giessmann T; Luetjohann D; Wegner D; Rosskopf D; Weitschies W; Siegmund W
Clin Pharmacol Ther; 2006 Nov; 80(5):477-85. PubMed ID: 17112804
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
Kosoglou T; Statkevich P; Johnson-Levonas AO; Paolini JF; Bergman AJ; Alton KB
Clin Pharmacokinet; 2005; 44(5):467-94. PubMed ID: 15871634
[TBL] [Abstract][Full Text] [Related]
6. Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (-/-) mice.
Oswald S; Koll C; Siegmund W
J Pharm Sci; 2007 Dec; 96(12):3478-84. PubMed ID: 17828742
[TBL] [Abstract][Full Text] [Related]
7. A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1.
Oswald S; Scheuch E; Cascorbi I; Siegmund W
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jan; 830(1):143-50. PubMed ID: 16280261
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.
Reyderman L; Kosoglou T; Statkevich P; Pember L; Boutros T; Maxwell SE; Affrime M; Batra V
Int J Clin Pharmacol Ther; 2004 Sep; 42(9):512-8. PubMed ID: 15487810
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of ezetimibe.
Simard C; Turgeon J
Can J Clin Pharmacol; 2003; 10 Suppl A():13A-20A. PubMed ID: 14571304
[TBL] [Abstract][Full Text] [Related]
10. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
11. Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects.
Bae JW; Choi CI; Lee JH; Jang CG; Chung MW; Lee SY
Eur J Clin Pharmacol; 2011 Jan; 67(1):39-45. PubMed ID: 20865252
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects.
Chu NN; Chen WL; Xu HR; Li XN
Clin Drug Investig; 2012 Dec; 32(12):791-8. PubMed ID: 23109219
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
14. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers.
Reyderman L; Kosoglou T; Boutros T; Seiberling M; Statkevich P
Curr Med Res Opin; 2004 Sep; 20(9):1493-500. PubMed ID: 15383199
[TBL] [Abstract][Full Text] [Related]
16. Disposition and biotransformation of the antipsychotic agent olanzapine in humans.
Kassahun K; Mattiuz E; Nyhart E; Obermeyer B; Gillespie T; Murphy A; Goodwin RM; Tupper D; Callaghan JT; Lemberger L
Drug Metab Dispos; 1997 Jan; 25(1):81-93. PubMed ID: 9010634
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.
Polsky-Fisher SL; Vickers S; Cui D; Subramanian R; Arison BH; Agrawal NG; Goel TV; Vessey LK; Murphy MG; Lasseter KC; Simpson RC; Vega JM; Rodrigues AD
Drug Metab Dispos; 2006 Jun; 34(6):1004-11. PubMed ID: 16510541
[TBL] [Abstract][Full Text] [Related]
18. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
19. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
[TBL] [Abstract][Full Text] [Related]
20. Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2.
de Waart DR; Vlaming ML; Kunne C; Schinkel AH; Oude Elferink RP
Drug Metab Dispos; 2009 Aug; 37(8):1698-702. PubMed ID: 19443695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
